Varlilumab ELISA Kit,96T,DB796018-96T,Abinscience

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant human CD27 antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Varlilumab in the sample competitively binds to the pre-coated protein with biotin-labeled Varlilumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Varlilumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 20% prior to the expiration date under appropriate storage condition.
Detection method	Colorimetric
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity	0.156 μg/ml
Range	0.31-5 μg/mL
Recovery	80-120%
Background	Varlilumab (CDX-1127), a human IgG1κ monoclonal antibody, targets CD27 receptor through reacting with the ligand binding site of CD27. CD27 is a member of the tumor necrosis factor receptor superfamily and expressed on unstimulated T lymphocytes, serving as a potent costimulatory molecule. It has been found that CD27 induces a series of T-cell reactions including T-cell activation, proliferation, survival, and maturation of effector capacity and T-cell memory together with its ligand CD70, which is transiently expressed on antigen-presenting cells. Besides, the interaction of CD27 and CD70 also stimulate B-cell proliferation, generation of plasma cells, production of immunoglobulin and B-cell memory, and induction of the cytolytic activity of natural killer (NK) cells. Moreover, CD27 is considered to function on tumor expansion and activation as it also expressed by regulatory T cells (Tregs), a cell that is associated with the suppression of antitumor immunity. The drug, developed by Celldex Therapeutics, is designed for immunotherapy for patients with solid tumors and hematologic malignancies. Varlilumab is currently conducted with two trails. One is the phase 1B clinical trial for advanced breast or ovarian cancer in combination with ONT-10. Another is the phase 1/2 trial for advanced refractory solid tumors together with anti-PD-1 nivolumab.
Alternative Names	1F5, CDX-1127, CAS: 1393344-72-3
Shipping	2-8 ℃
Specifications	Varlilumab
Note	For Research Use Only.